Papers/PMID:36303266
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.
European journal of heart failure2023The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
spironolactone — decreases mitral E/e' ratio
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Spironolactone reduced LAVi by -1.1 (-2.0 to -0.1) ml/m2 (p = 0.03); LVMi by -3.6 (-6.4 to -0.8) g/m2 (p = 0.01); IVS thickness by -0.2 (-0.3 to -0.1) mm (p = 0.01); E/e' ratio by -1.3 (-2.4 to -0.2) (p = 0.02); and increased LVEF by 1.7 (0.8-2.6)% (p < 0.01).”
Quoted verbatim from Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.. - Study
- meta-analysis
- Population
- Patients with stage B or C heart failure with preserved ejection fraction, individual-patient-data pooling of HOMAGE, Aldo-DHF and TOPCAT; spironolactone versus placebo or control, 9-12 month exposure
Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.2023PMID:36303266Permalink